The appointment adds biopharma governance and investment expertise to the board. Traders should monitor for potential strategic shifts given Dr. Doux’s background in rare disease therapeutics and prior board experience, though no immediate changes are indicated.
Price Chart
Executive Summary
Palvella Therapeutics appointed John Doux, M.D., to its Board of Directors as a Class III member, effective April 13, 2026. Dr. Doux brings extensive experience in dermatology, biotech investing, and corporate governance from prior board roles in healthcare companies.
Key Facts
- John Doux, M.D., was appointed to the Board of Directors effective April 13, 2026
- Board size increased from six to seven members
- Dr. Doux is a board-certified dermatologist and healthcare investor at Palo Alto Investors LP
- He previously served on Palvella's board from 2019 to 2022 prior to its reverse merger
- No departures or executive officer changes announced
- Dr. Doux received an option grant to purchase 6,000 shares, vesting monthly over 36 months
Financial Impact
Minimal near-term financial impact; option grant for 6,000 shares represents minor potential dilution
Risk Factors
- Minimal execution risk as this is a board expansion, not a C-suite change
- Potential for increased investor scrutiny due to Dr. Doux’s analytical background
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-151979 |
| Document: 0001193125-26-151979-index-headers.html | 0001193125-26-151979 |
| Document: 0001193125-26-151979-index.html | 0001193125-26-151979 |
| Document: 0001193125-26-151979.txt | 0001193125-26-151979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access